Insulin-degrading enzyme higher in subjects with metabolic syndrome
| Autor: | Sigal Shaklai, Yuval Nash, Dan Frenkel, Nathan Landis, Miri Margaliot, O. Fursht, Etty Osher, Brurya Tal, Naftali Stern, Karen Tordjman, I. Goldiner, Itai Benhar, Jessica Sack, Guy Goldsmith, E. B. Touati, Yael Sofer, Merav Serebro, Yonit Marcus, Gabi Shefer, W. Abu Ahmad, M. Yacobi Bach, Limor Nahary |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism medicine.medical_treatment 030209 endocrinology & metabolism Insulysin 03 medical and health sciences 0302 clinical medicine Endocrinology Insulin resistance Diabetes mellitus Internal medicine Insulin-degrading enzyme Medicine Humans Insulin Prediabetes Abdominal obesity Metabolic Syndrome biology C-Peptide business.industry Glucose Tolerance Test medicine.disease Insulin receptor 030220 oncology & carcinogenesis biology.protein medicine.symptom Metabolic syndrome business |
| Zdroj: | Endocrine. 71(2) |
| ISSN: | 1559-0100 |
| Popis: | Metabolic syndrome (MS) is comprised of a cluster of abnormalities in glucose, lipid, and vascular homeostasis, which is most commonly linked to abdominal obesity. MS heralds increased risk for development of diabetes and is linked to impairment in insulin signaling. Insulin-degrading enzyme (IDE) is one of the mechanisms through which insulin blood levels are maintained. It has been previously suggested that controlling IDE levels could provide yet another potential therapeutic approach in diabetes. Here we aim to investigate whether changes in serum IDE levels correlate with the severity of MS. Using a highly sensitive ELISA assay of active IDE in human serum, we found a strong correlation between circulating IDE levels and circulating levels of triglycerides, insulin, and c-peptide and an inverse correlation with HDL cholesterol (HDLc). Serum IDE levels were higher in MS subjects than in control subjects. Hence, circulating IDE may serve as a tool to identify subjects with abnormal insulin metabolism, possibly those with MS that are at risk to develop diabetes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink